Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

AI-Driven Healthcare and Health Informatics: Machine Learning, Nan carrier Drug Delivery, Computational Methods, Cybersecurity, and Quality Assurance

Ali Husnain[1*]

[1]Chicago State University

[1]ahusnain@csu.edu

open access

Corresponding Author

Ali Husnain
ahusnain@csu.edu

Article History:

Submitted: 02-07-2025

Accepted: 07-08-2025

Published: 12-08-2025

Keywords

AI in healthcare, machine learning, health informatics, nanocarrier drug delivery, computational modeling, quality assurance, cybersecurity.

ABSTRACT

Combining Artificial Intelligence (AI), machine learning (ML), and health informatics are transforming the contemporary healthcare through the provision of predictive, personalized, and effective patient care. Combined with nanocarrier-based drug delivery systems, such as cubosomes, phytosomes, SMEDDS, and organogels, computational pharmacology maximizes the solubility, bioavailability, and target delivery of drugs. At the same time, the strong cybersecurity solutions and quality assurance systems guarantee the integrity of the data, its models, and their compliance with the various regulations. This review outlines interdisciplinary innovations that have brought AI, computational modeling, and pharmaceutical innovation together and the transformative potential in precision medicine. The future directions are aimed at addressing the issues of data heterogeneity, ethics, and clinical translation.

INTRODUCTION

Artificial Intelligence (AI) is changing the way the diseases are treated, managed, and diagnosed by revolutionizing the healthcare ecosystem globally. The swift adoption of AI technologies (including machine learning (ML) algorithms and more sophisticated data analytics) has led to the emergence of a new generation of health informatics, in which intelligent systems can help healthcare providers

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

make decisions more quickly and more accurately [1]. Healthcare AI aims at using computational capability and data science to process massive volumes of clinical data (including electronic health records (EHRs), imaging information, genomic data, and medical history) to deliver actionable information to support personalized and preventive care [2].

Health informatics is the engine of this change as it facilitates a smooth collection, storage, analysis, and sharing of healthcare data in digital platforms. With the incorporation of AI, health informatics systems are now able to go beyond simple record keeping and become intelligent systems that can predictively model and track diseases and aid in clinical decision-making. Machine learning algorithms are being trained to identify disease indicators of the complex diseases like cancer, diabetes, and cardiovascular diseases earlier in advance, which greatly increases the accuracy of the diagnosis and patient recovery rates [3].

New developments have also shown how AI can be used in the sciences of drug delivery and pharmaceuticals to combine computational technologies with nanomedicine. The application of superior nanocarrier systems that include cubosomes which improves the solubility, stability and targeted delivery of anticancer drugs. Equally, phytosomes and organogels have become an attractive delivery platform, which fits the notion of precision medicine. When combined with AI and computational modeling, these drug delivery systems make formulations predictable and thus less susceptible to trial-and-error methods, and more efficient in therapeutic efficacy [4].

Moreover, computer science and health converge to facilitate the creation of secure and scalable architecture used in the management of healthcare data. With the ongoing digitalization of healthcare, the necessity of cybersecurity has been an essential aspect. To secure patient trust and guarantee that the data protection regulations are observed, AI-enabled systems should be resistant to data breaches, malicious attacks, and unauthorized access [5]. It is also noteworthy that quality assurance (QA) plays an important role in AI-based healthcare systems.

The accuracy, reliability, and safety of the AI models, nanocarrier formulations, and health data systems should be verified with the help of QA frameworks before the implementation of such tools in clinical practice. This helps in the fact that emerging technologies do not only increase efficiency but also maintain patient safety and regulatory quality. AI, machine learning, nanocarrier drug delivery, health informatics, cybersecurity, and quality assurance are important milestones to the future of intelligent healthcare systems, where, even more than ever, technology and biology come together to deliver customized, safe, and effective medical treatment [6].

Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

ARTIFICIAL INTELLIGENCE IN MEDICAL PRACTICE

Machine Learning (ML), which is one of the most important branches of Artificial Intelligence (AI), has become one of the backbones of healthcare innovation in the modern world. ML provides transformative opportunities in the fields of diagnostics, treatment planning, patient monitoring, and drug development by allowing computers to learn data and optimize performance without providing explicit instructions, thus offering an opportunity to transform the realm. Its connection with the health informatics systems will enable healthcare professionals to analyze large amounts of data, determine concealed patterns, and make evidence-based decisions that will improve clinical outcomes and operational efficiency [7].



Figure: 1 showing applications of AI in medical practice

The field of predictive analytics and diagnosis of diseases is one of the deepest uses of ML in healthcare. Machine learning algorithms have the potential to handle more complicated data sets,

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

such as medical imaging, genomic data, and electronic health records (EHRs), to predict disease risk, detect early pathological changes otherwise invisible to the human eye [8]. As an example, deep learning features have proved to be very precise in identifying cancers with radiographic images, and supervised learning algorithms are currently being implemented to predict cardiovascular occurrences with patient-specific factors like cholesterol levels, blood pressure, and genetic background [9].

ML is also important in personalized medicine whereby the treatment regimens are customized to the profiles of individual patients. The patient-specific data, drug response history and lifestyle factors are analyzed using algorithms that suggest customized therapies to minimize the side effects and maximize therapeutic outcomes. As an illustrative example, with reference to nanocarrier-based drug delivery systems (cubosomes, phytosomes, and organogels) investigated by ML models may be used to estimate the best formulation parameters, release kinetics, and bioavailability, which circumvents the reliance of such systems on conventional trial and error experimentation [10].

In health informatics, ML allows automated routine administrative functions, including clinical documentation, scheduling appointments and billing, which relieves the pressure on the healthcare staff and increases its efficiency. The ML technique of Natural Language Processing (NLP) allows interpreting unstructured data such as clinical notes, medical literature, and pathology reports intelligently to convert them into actionable information. Such integration enhances decision support systems and leads to evidence-based medicine [11].

Additionally, ML helps in real-time monitoring of patients and early warning. Physiological data is constantly monitored by wearable devices and remote sensors, which are run on the basis of ML algorithms to identify irregularities in the body, including arrhythmias, hypoglycemia, or respiratory distress. The presence of such proactive monitoring will enable timely medical intervention which may save lives in life and death situations [12]. Nevertheless, along with enormous opportunities, the application of ML in healthcare is associated with issues of data privacy, algorithm transparency, and validation as well.

Adequate cybersecurity to safeguard sensitive patient information and a high standard of quality assurance in the output of the algorithms will be required to build trust in the use of algorithms in healthcare [13]. Intelligent, predictive, and patient-centered healthcare systems are on the verge of coming into existence due to the intersection of machine learning and health informatics, nanotechnology, and computational modeling. With the help of the incessant learning based on the data, ML allows creating a future in which medicine will be more accurate, efficient, and even more humane and personal [14].

Global Journal of Machine Learning and Computing

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

NANOCARRIER-BASED DRUG DELIVERY SYSTEMS

The example of nanocarrier-based drug delivery systems has become a revolutionary process within the pharmaceutical sciences, which provides an innovative solution to drug solubility, stability, bioavailability and targeted delivery issues. Combination of nanotechnology and pharmaceutical formulation design has seen the emergence of multifunctional platforms as cubosomes, phytosomes, supersaturable self-microemulsifying drug delivery systems (SMEDDS), and organogels to initiate vast improvements in therapeutic efficacy with a minimal number of side effects [15]. These innovations are currently being extended to further improvements and refinement by means of AI-based modeling, search optimization by use of machine learning (ML), and computation simulations, making the drug delivery process more accurate, efficient, and patient-centered [16].

Cubosomes are some of the most promising nanocarriers that have incredible structural and functional characteristics, which belong to the next generation. Cubosomes are bicontinuous cubic liquid crystalline nanoparticles that can entrap both lipophilic and hydrophilic drugs. They possess a special architecture that enables prolonged and regulated release of anticancer agents, which enhance the localization of drugs to the tumor region and reduce the toxicity seen in the body. Cubosomes are especially beneficial to cancer treatment and other chronic diseases that need extended exposure to drugs due to such properties [17]. Provide a new platform on which the bioavailability of phytochemicals and herbal extracts in cancer treatment can be improved. Phytosomes enhance the lipophilicity, absorption and stability of natural anticancer agents by forming a complex with phospholipids and plant-derived bioactive compounds. Phytochemistry coupled with nanotechnology guided by computational modeling will facilitate the prediction and optimization of drug-carrier interactions thereby guaranteeing improved consistency in therapeutic effects [18].

The other interesting development is the supersaturable self-microemulsifying drug delivery system (SMEDDS) where polymeric precipitation inhibitors are used to improve the solubility and bioavailability of poorly water-soluble compounds. With the addition of AI and Quality by Design (QbD) techniques, scientists have one way to systematically optimize SMEDDS formulations with the idea of reproducibility and scalability in drug manufacturing [19]. Moreover, organogels have also attracted attention as new oral and topical controlled-release the organogels have been developed to control the delivery of drugs such as nifedipine with excellent biocompatibility and stability. Their semi-solid characteristics give them distinct benefits in localized and sustained delivery, and in computer modeling their rheological and diffusion characteristics can be precisely manipulated to give a high degree of accuracy in therapy [20].

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

The integration of AI and ML algorithms with nanocarrier design, critical formulation variables, including particle size, drug loading, release kinetics, and others, can be predicted, eliminating the need to undergo massive laboratory experimentation. Besides, drug distribution can be simulated, and patients can be predicted to respond, which is why the AI-driven systems match the objectives of personalized medicine [21]. Drug delivery systems that realize nanocarriers improved with the methods of computational techniques and AI are changing the future of contemporary therapeutics. Providing versatile, specific, and regulated drug delivery, cubosomes, phytosomes, SMEDDS, and organogels have a massive potential to treat such complex illnesses as cancer. The combination of health informatics, cybersecurity and quality assurance structures also make sure that these innovations are safely and successfully translated in the laboratory to the clinic [22].

COMPUTATIONAL STRATEGIES IN PHARMACEUTICAL DESIGN AND MEDICINE

Computational methods now form a fundamental part of contemporary healthcare and pharma research, and such methods have been providing a balance between experimental research and data-driven innovation. With the help of Artificial Intelligence (AI), machine learning (ML), and more sophisticated computational modeling, researchers and clinicians are able to design, optimize, and provide more successful treatments, use less time, less money, and less uncertainty in the experiment. Computational techniques may be applied in the design of drugs to model drug delivery and pharmacokinetic effects, optimize drug delivery systems based on nanocarriers, such as cubosomes, phytosomes, SMEDDS, and organogels [23].

Drug formulation and optimization is one of the important uses of computational methods. Molecular docking, quantitative structure-activity relationship (QSAR) and molecular dynamics simulations are tools that enable researchers to predict the interaction between drugs and biological targets at the molecular level. Indicatively, computational modeling has been applied to modify cubosome and phytosome formula to yield a better bioavailability and release of drugs as illustrated [24]. Through modeling of drug-carrier, scientists are able to anticipate the solubility, stability, and the rate of release without necessarily conducting extensive trail and error experimentation to find the answer hence enhancing efficiency and accuracy in drug development [25].

Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75



Figure: 2 showing computational strategies in Pharmaceutical Design

Quality by Design (QbD) is a methodical process that is focused on in pharmaceutical innovation and incorporates the use of computational tools to guarantee effective and reliable drug delivery systems. With AI-based modeling, key variables of formulation (particle size, viscosity, and drug loading) may be fine-tuned to attain the desired therapeutic outcome. Indicatively, the organogels designed and advanced. Through the use of QbD principles enabled by computational modeling provided uniformity of drug performance and quality of regulatory approval [26].

Computational methods in healthcare are not only based on the design of drugs but also can be used in clinical decision support, predictive analytics, and patient-specific modeling. Electronic health records, images, and genomic data can be analyzed by AI algorithms and provide insights into disease patterns, disease progression, and recommendations on the personalized approach to treatment. Machine learning models are also applicable in real-time monitoring of treatment responses to make dynamic changes in therapy so as to ensure optimal efficacy and minimal adverse effects [27].

In addition, computational healthcare systems are associated with cybersecurity and data integrity. With more and more patient information and drug design models becoming computerized, clear platforms of computation must be safeguarded to avoid unauthorized access, data breach and manipulation of sensitive information. To protect these online healthcare settings, AI-driven intrusion detection systems, encryption algorithms, and block chain technologies are being incorporated to

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

protect them [28].

Lastly, computational methods are used to promote quality assurance (QA) in pharmaceutical and health care settings. The drug delivery systems can be pre-validated with predictive modelling and simulation and ongoing monitoring and automated analysis ensure the compliance with the regulatory requirements and clinical safety measures. These approaches help to transform the complicated research into scaled, secure, and workable medical solutions. Computational methods in healthcare and drug design constitute a very important crossroad of technology biology and informatics [29]. These approaches, supported by intensive quality control and cybersecurity, are changing the principles of developing advanced nanocarrier drugs systems and providing intelligent, personalized, and safe healthcare solutions [30].

CYBERSECURITY IN HEALTHCARE INFORMATICS

With the digitization of healthcare systems, cybersecurity has become a major issue of concern in the protection of patient data, medical equipment, and AI-based health systems. The convergence of electronic health records (EHRs), telemedicine, wearable sensors, and cloud-based computing has developed large networks of sensitive data, which are appealing targets of cyberattacks. Ensuring the confidentiality, integrity and availability of healthcare information is important not only to meet regulatory requirements, but also to ensure patient safety and confidence in contemporary healthcare systems [31].

Healthcare informatics is based on the gathering, storing, and analyzing of big data, which may involve personally identifiable data, genomic data, and treatment history. The decision-making process is optimized with the help of AI and machine learning algorithms that analyze those complicated datasets, but the effectiveness of these algorithms depends on whether the underlying data is secure or not [32]. Weaknesses in the network infrastructure, software and medical devices may put sensitive data at the risk of ransom ware attacks, data breach, and unauthorized manipulation. The possibility of inaccurate predictions or misdiagnosis of a compromised AI model with potentially serious clinical implications is possible [33].

To overcome these threats, well-developed cybersecurity models are being incorporated in the healthcare informatics systems. End-to-end encryption, multi-factor authentication, secure data transmission protocols, and block chain-based record-keeping techniques will allow keeping data safe at each point of its collection, processing, and storage. Machine learning can also be used in cybersecurity, and the algorithms can identify suspicious dynamics, recognize possible intrusions, and act upon the threats in real time [34]. There are also concerns in regard to the cybersecurity of drug delivery systems and nanocarrier-based therapies. With the emergence of only computational

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

models and AI-based design tools directing the design and optimization of formulations such as cubosomes, phytosomes, and organogels, it is essential to defend intellectual property and clinical trial data against cyber attackers. To make sure that these digital assets are secure not only the scientific innovation is being safeguarded but also the health outcomes of the patients [35].

Cybersecurity is also related to quality assurance (QA) as it guarantees the reliability and integrity of digital healthcare systems. Secure platforms mitigate the chances of data corruption or unauthorized manipulations, facilitate the stability in the execution of AI models, foreseeable analytics, and health informatics applications. Cybersecurity is becoming an important aspect of clinical QA regulated by regulatory standards, due to its critical nature in the contemporary healthcare provision. Cybersecurity is one of the primary constituents of modern healthcare informatics [36]. Through data protection, AI models security, and protection of the computing drug delivery system, effective cybersecurity measures will facilitate secure, trustworthy and reliable healthcare services, which will assist the greater objectives of AI integration, precision medicine, and quality assurance [37].

AI AND DRUG DELIVERY SYSTEMS QUALITY ASSURANCE.

Quality Assurance (QA) is an essential part of health care as well as pharmaceutical systems that provide higher standards of safety, efficacy and reliability of both products, processes, and technologies. As the use of Artificial Intelligence (AI), machine learning (ML), and sophisticated nanocarrier-based drug delivery systems continues to rise, QA is no longer about the control of the process but a holistic approach to consider all the computational validation, clinical compliance, and monitoring. QA in the context of AI-driven healthcare is used to make sure that predictive models, decision-support systems and analytical tools are used in healthcare with accuracy, reproducibility and transparency [38]. Machine learning algorithms are trained using large data and they may be biased, have data quality problems or lack sufficient validation. Anomalies, error reduction, and confidence in automated healthcare solutions can be achieved by QA processes including strict cross-validation, cross-vetting against clinical standards, and post-implementation monitoring. Particularly, this is of great importance when high-stakes decisions are made based on AI, including cancer diagnosis or individual treatment advice [39].

On the same note, QA plays a vital role in design and implementation of drug delivery systems based on nanocarriers like cubosomes, phytosomes, SMEDDS, and organogels. These systems are developed to maximize solubility, stability and targeted release of therapeutic agent as underscored in research works. QA parameters guarantee that the formulation parameters such as particle size, encapsulation efficiency, drug loading and release kinetics are always realized. Methods like failure mode testing through in vitro release, rheological testing, and stability testing is combined with

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

computational analysis and artificial intelligence forecasting to ensure that the test outcomes match the expectations of the design [40].

In addition, the QA also involves regulatory compliance and documentation. Pharmaceutical and healthcare products are to comply with the national and international standards such as Good Manufacturing Practices (GMP), ISO certifications, and regulations by the regulatory agencies. The combination of QA and AI and ML will guarantee that the digital models and the physical formulations are subjected to high levels of safety, efficacy, and reproducibility before a clinical trial [41]. QA also promotes cybersecurity and data integrity of the computing systems. Confirmed and tested platforms mitigate unauthorized access, data corruption, or manipulation of AI models and thus ensure the predictive analytics and healthcare informatics do not fail. Such a combination of QA and cybersecurity is essential in ensuring patient safety and trust in AI-based solutions to healthcare [42]. Conclusively, Quality Assurance in AI and drug delivery systems offers an orderly way of ensuring safety, performance, and adherence. Through experimental validation, computational validation, regulatory compliance, and cybersecurity measures, QA will provide assurance that innovative healthcare solutions, both nanocarrier formulations and AI-based predictive models, will provide effective, reliable and safe patient outcomes [43].

CHALLENGES AND FUTURE PERSPECTIVES

Artificial Intelligence (AI), machine learning (ML), drug delivery systems based on nanocarriers, and health informatics are changing the contemporary healthcare. Yet, there are a number of issues that should be overcome in order to exploit the potential of these technologies completely. Complexity of healthcare data is one of the main challenges. Patient data can be highly heterogeneous, spread across a variety of platforms and may consist of unstructured clinical notes, imaging data, genomic sequences and real-time monitoring results. To produce high-quality, interoperable data to support AI and ML models, it is vital to ensure high quality and interoperability of data to derive accurate, reliable, and clinically relevant insights. The second potential obstacle is regulatory and ethical factors [44]. AI-empowered decision support systems and sophisticated drug delivery platforms should meet high requirements that guarantee the safety of patients, their effectiveness, and transparency. The regulations on the emerging technologies, such as nanocarrier based formulations and predictive analytics, are still developing. Through ethical considerations, including algorithmic bias, data privacy, and informed consent, the problem has to be addressed in a systematic manner to ensure the population remains trustful [45].

The threat to cybersecurity is also highly topical because, with the digitization of healthcare, data breach, ransom ware attack, and manipulation of AI models can be seen as openings. It is necessary

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

to encrypt sensitive patient information and proprietary research data using robust encryption and secure cloud environments and AI-based threat analysis solutions. At the same time, quality assurance (QA) should also adapt to check the physical drug delivery systems, as well as computational models, and make sure that the results of the experiment, predictions provided by the AI, and clinical practices are always safe. Nevertheless, the future of the integrated AI, the nanotechnology, and the world of computational healthcare remains bright [46]. It is projected that these innovations in the predictive modeling and individual medicine, such as smart systems of drug delivery will transform the treatment plans, patient outcomes, and health care expenses. AI and ML can be further used to optimize nanocarrier systems such as cubosomes, phytosomes, SMEDDS, and organogels to give desired, controlled, and effective release of drugs [47].

The continuing pollution of the environment with heavy metals, polycyclic aromatic hydrocarbons, and endocrine-disrupting chemicals are becoming a major contributor to cancer risk. Cohort community studies have also shown that there are strong relationships between the long-term exposure of such pollutants and high rates of several types of cancer including breast, lung and liver cancers. The combination of AI and machine learning with health informatics can complement the analysis of big epidemiological data and allow finding the patterns of pollutants exposure, the at-risk groups, and the possible preventive measures. These methods offer a factual model of connecting the environmental risk factors and disease outcomes [48].

In addition, further advancement of health informatics, cybersecurity, and QA systems will make sure that digital healthcare systems are safe, approved, and patient-oriented. The combination of computing technology with experimental studies is the plunge towards a future of predictive, personalized, and precise healthcare. The combination of multidisciplinary efforts, such as computer science, pharmacology, biotechnology, and clinical medicine, will be central to eliminating the current shortcomings and speeding up the process of implementing these technologies in practice and in clinical settings [49]. Although data quality, regulatory, and cybersecurity issues and QA concerns are a reality, the opportunities of integrating AI, ML, nanocarrier drug delivery, and health informatics are unprecedented. The future of healthcare is bound to be intelligent, safe and highly personal with future research, innovation and cross-disciplinary collaboration [50].

CONCLUSION

The emergence of Artificial Intelligence (AI), machine learning (ML), health informatics, and nanocarrier-based drug delivery systems is initiating a paradigm shift in the contemporary healthcare. This interdisciplinary approach makes it possible to deliver predictive, individualized, and effective care to patients, which is in contrast to the old, reactive models of treatment. AI and ML offer potent

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

analytical tools with the ability to analyze huge and complicated data to identify actionable information, enhance the accuracy of diagnostics, and optimize treatment options. Health informatics is the foundation of this ecosystem, which enables the safe gathering, storage, and analysis of patient information as well as real-time decision-making.

Examples Nanocarrier-based drug delivery systems, such as cubosomes, phytosomes, supersaturable self-microemulsifying drug delivery systems (SMEDDS), and organogels, can be considered tangible examples of the advantages of the combination of computational modeling with pharmaceutical development. These systems can improve drug solubility, bioavailability, and target delivery to present substantial increases in efficacy and safety to treatments like cancer treatment. The use of AI and computational methods also enables scientists to model formulation behavior, optimize release kinetics, and personalize treatment to patient profiles and eliminates the need to rely on experiment-based labor-heavy testing.

Simultaneously, in the same direction, cybersecurity and quality assurance (QA) also form part of the trust, safety, and regulatory standards operating within AI-supported healthcare systems. Sensitive patient information and model reliability are also critical to the safe use of advanced healthcare technologies. QA systems are used to certify not only computational models, but also experimental drug delivery systems, making sure that innovations are always up to clinical standards. The combination of all these factors protects patient result and builds trust in new technologies.

Moving to the future, AI, ML, nanotechnology, and informatics methods can be integrated to create unmatched possibilities to improve healthcare delivery. The further development of predictive analytics, personalized therapeutics, and safe data management will enhance the outcomes of patients, minimize costs, and simplify clinical workflow. The obstacles are still there, such as heterogeneity of the data, regulatory issues, and ethical issues, and multidisciplinary collaboration and active research can overcome these barriers.

Intersection of technology, biology and informatics is the future of the healthcare. The healthcare ecosystem transforms into an even smarter, more personal, safer, and efficient paradigm as it incorporates AI, machine learning, computational solutions, nanocarrier-based drug delivery, cybersecurity, and quality assurance. Such combined innovations can transform the way patients are treated bringing an age of precision medicine that is clinical in its effectiveness and technological in its strength.

Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

REFERENCES

[1]. Kabeer MM. Leveraging AI for Process Optimization: The Future of Quality Assurance in Lean Six Sigma. American Journal of Artificial Intelligence and Computing. 2025 May 7;1(1):87-103.

[2]. Dave P, Raval B, Dudhat K. Cubosomes: Next-Generation Nanocarriers for Versatile Drug Delivery System for Cancer Therapy and Other Applications. Biomedical Materials & Devices. 2025 Jun 5:1-32.

[3]. Singh A. Artificial Intelligence and Its Expanding Role in Computer Science. American Journal of Artificial Intelligence and Computing. 2025 Sep 20;1(2):226-40.

[4]. Javeedullah M. Healing with Data: The Power and Promise of Health Informatics. Global Research Repo. 2025 Sep 9;1(2):310-29.

[5]. Bacha A, Zainab H. AI for Remote Patient Monitoring: Enabling Continuous Healthcare outside the Hospital. Global Journal of Computer Sciences and Artificial Intelligence. 2025 Jan 23;1(1):1-6.

[6]. Kabeer MM. AI in Lean Six Sigma: A Review of Industrial Implementations, Benefits, and Barriers. Global Science Repository. 2024 Jan 10;1(1):137-61.

[7]. Javeedullah M, Zeb S. Privacy, Policy, and Progress: Reviewing the Regulatory Landscape in Health Informatics. Global Research Repo. 2025 Sep 3;1(2):112-28.

[8]. Singh A. Foundations and Frontiers in Theoretical Computer Science: A Review of Key Concepts and Open Problems. Global Research Repo. 2025 Sep 3;1(2):154-82.

[9]. Bacha BA, Ahmad S, Ahmad R, Ahmad I. Coherent manipulation of vectorial soliton beam in sodium like atomic medium. Chaos, Solitons & Fractals. 2024 May 1;182:114856.

[10]. Singh A. A Survey of Foundational Concepts and Emerging Frontiers in Computer Science. Global Research Repo. 2025 Sep 9;1(2):279-309.

[11]. Ekpan FM, Ori MO, Samuel HS, Egwuatu OP. The synergy of AI and Drug delivery: A Revolution in Healthcare. International Journal of Advanced Biological and Biomedical Research. 2024 Jan 1;12(1):45-67.

[12]. Khanna A, El Barachi M, Jain S, Kumar M, Nayyar A, editors. Artificial intelligence and machine learning in drug design and development. John Wiley & Sons; 2024 Jul 18.

[13]. Dave P, Kariya S, Dudhat K. Tailoring and optimizationn of nifedipine controlled release organogel via quality by design approach. Journal of Pharmaceutical Innovation. 2024 Aug;19(4):47.

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

[14]. Kabeer MM. Synergizing AI and Lean Six Sigma: A Comprehensive Review of Smart Quality Assurance Systems. Global Science Repository. 2024 Jan 5;1(1):116-36.
[15]. Singh A. Exploring Innovations across Computer Science Disciplines. Global Research Repo. 2025 Sep 9;1(2):330-61.
[16]. Mazumdar H, Chakraborty C, Sathvik MS, Jayakumar P, Kaushik A. Optimizing pix2pix gan with attention mechanisms for ai-driven polyp segmentation in iomt-enabled smart healthcare. IEEE Journal of Biomedical and Health Informatics. 2023 Oct 31.
[17]. Bacha A. Unveiling Frontiers: Hybrid Algorithmic Frameworks for AI-Driven Mental Health Interventions. AlgoVista: Journal of AI and Computer Science. 2025;2(1):1-8.
[18]. Malik YG. Artificial Intelligence in Food Systems: Expanding Horizons across Healthcare, Cybersecurity, and Generative AI. Global Food Research. 2025 Aug 28;1(1):45-71.
[19]. Singh A. Human-Computer Interaction: A Review of Usability, Design, and Accessibility Trends. Global Research Repo. 2025 Sep 9;1(2):362-87.
[20]. Javeedullah M. Empowering Patients through Health Informatics: Trends, Challenges, and Opportunities. Global Research Repo. 2025 Sep 3;1(2):1-7.
[21]. Shehzad K, Munir A, Ali U. Modern Trends in Food Production: the Role of AI in Smart Food Factories. Global Journal of Emerging AI and Computing.;1(2):1-30.
[22]. Dave P, Jani R, Chakraborthy GS, Jani KJ, Upadhye V, Kahrizi D, Mir MA, Siddiqui S, Saeed M, Upadhyay TK. Phytosomes: A promising delivery system for anticancer agents by using phytochemicals in cancer therapy. Cellular and Molecular Biology. 2023 Dec 20;69(14):1-8.
[23]. Faiyazuddin M, Chaudhari Y, Chaudhari M, Gholap AD, Sundaram G, Alam MI, Webster TJ. Navigating Nanotechnology Healthcare Horizons: A Comprehensive Review of IoT and SIoT Evolution for Patient-Centric Perspectives. Journal of Biomedical Nanotechnology. 2024 Dec 1;20(12):1791-803.
[24]. Khan M, Bacha A. Neural Pathways to Emotional Wellness: Merging AI-Driven VPSYC Systems with EEG and Facial Recognition. Global Trends in Science and Technology. 2025 Jan 26;1(1):53-62.
[25]. Shehzad K, Ali U, Munir A. Computer vision for food quality assessment: Advances and challenges. Available at SSRN 5196776. 2025.
[26]. Sherani AM, Bacha A. Pioneering Advances in AI-Driven Detection and Therapy for Mental Health Challenges. Global Insights in Artificial Intelligence and Computing.;1(1):57-67.
[27]. Kabeer MM. Utilizing Machine Learning for Continuous Process Improvement in Lean Six Sigma. Global Trends in Science and Technology. 2025 May 7;1(2):49-63.

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

[28]. Shah HH, Bacha A. Leveraging AI and Machine Learning to Predict and Prevent Sudden Cardiac Arrest in High-Risk Populations. Global Journal of Universal Studies. 2024 Dec 15;1(2):87-107.

[29]. Javeedullah M. Future of Health Informatics: Bridging Technology and Healthcare. Global Trends in Science and Technology. 2025 Apr 4;1(1):143-59.

[30]. Singh A. Intelligent Machines: Shaping the Future of Computer Science and Society. Global Research Repo. 2025 Sep 9;1(2):254-78.

[31]. Khan M, Bacha A. AI-Driven Cybersecurity in Healthcare: The Transformative Potential of Generative AI. Global Research Repo. 2025 Nov 3;1(3):157-81.

[32]. Wibowo MF, Pyle A, Lim E, Ohde JW, Liu N, Karlström J. Insights Into the Current and Future State of AI Adoption Within Health Systems in Southeast Asia: Cross-Sectional Qualitative Study. Journal of Medical Internet Research. 2025 Jun 16; 27:e71591.

[33]. DAVE P, PATEL D, RAVAL B, JANI R. SOLID SUPERSATURABLE SMEDDS: A POLYMERIC PRECIPITATION INHIBITOR TO ENHANCE SOLUBILITY AND BIOAVAILABILITY.

[34]. Neoaz N, Bacha A, Khan M, Sherani AM, Shah HH, Abid N, Amin MH. AI in Motion: Securing the Future of Healthcare and Mobility through Cybersecurity. Asian Journal of Engineering, Social and Health. 2025 Jan 29;4(1):176-92.

[35]. Kabeer MM. Automation Meets Accuracy: A Deep Dive into AI for Quality Assurance. Global Research Repo. 2025 Oct 25;1(3):138-56.

[36]. Abdalzaher MS, Krichen M, Shaaban M, Fouda MM. Quality-Focused Internet of Things Data Management: A Survey, Perspectives, Open Issues, and Challenges. IEEE Internet of Things Journal. 2025 Sep 24.

[37]. Bacha A. Artificial Intelligence in Healthcare, Cybersecurity, Machine Learning, and Food Processing: A Cross-Industry Review. American Journal of Artificial Intelligence and Computing. 2025 Jul 24;1(2):87-104.

[38]. Singh A. Fifty Years of Computer Science: Trends, Milestones, and Emerging Challenges. Global Research Repo. 2025 Sep 9;1(2):230-53.

[39]. Jamal A. Novel approaches in the field of cancer medicine. Biological times. 2023; 2(12):52-3.

[40]. Dave P, Raval B, Pujara N, Gohil T. FORMULATION AND EVALUATION OF ORAL SUPERSATURABLE SELF MICRO EMULSIFYING DRUG DELIVERY SYSTEM ITRACONAZOLE.

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.60-75

[41]. Singh A. From Algorithms to AI: A Comprehensive Review of Core Concepts in Computer Science. Global Research Repo. 2025 Sep 3;1(2):129-53.

[42]. Malik A, Solaiman B. AI in hospital administration and management: Ethical and legal implications. Research Handbook on Health, AI and the Law. 2024 Jul 16:20-40.

[43]. Liu Y, Cao X, Chen T, Jiang Y, You J, Wu M, Wang X, Feng M, Jin Y, Chen J. A survey of embodied ai in healthcare: Techniques, applications, and opportunities. arXiv preprint arXiv:2501.07468. 2025 Jan.

[44]. Javeedullah M. Predictive Modeling in Health Informatics: A Review of Applications in Population and Personalized Health. Global Science Repository. 2024 Jan 1;1(1):1-7.

[45]. Dave P, Patel D, Raval B. An oral organogel-novel approach for controlled drug delivery system. International Journal of Drug Delivery Technology. 2022;12(1):437-5.

[46]. Javeedullah M. Integrating Health Informatics Into Modern Healthcare Systems: A Comprehensive Review. Global Journal of Universal Studies. 2025 Apr 15;2(1):1-21.

[47]. Bacha A, Shah HH. AI-Enhanced Liquid Biopsy: Advancements in Early Detection and Monitoring of Cancer through Blood-based Markers. Global Journal of Universal Studies. 2024 Dec 15;1(2):68-86.

[48]. Rahman M. Persistent Environmental Pollutants and Cancer Outcomes: Evidences from Community Cohort Studies. Indus Journal of Bioscience Research. 2025 Aug 30;3(8):561-8.

[49]. Asediya V, Anjaria P, Dhial K, Pathak A. Artificial Intelligence and Machine Learning in Drug Delivery Optimization. InNext-Generation Drug Delivery Systems 2025 May 13 (pp. 499-521). New York, NY: Springer US.

[50]. Hagos DH, Alami HE, Rawat DB. Ai-driven human-autonomy teaming in tactical operations: Proposed framework, challenges, and future directions. arXiv preprint arXiv:2411.09788. 2024 Oct 28.